Latest Views & News

OptiBiotix Health – “in line” trading update, but now time for profitable delivery...

By Tom Winnifrith & Steve Moore | Friday 4 March 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

OptiBiotix Health (OPTI) has issued a trading update commenting that 2021 “total invoiced sales for the group were £2.2m (2020: £1.5m) an increase of 46.7% on the previous year and in line with market expectations” and including that it “has made good progress against its stated aims of focusing on a smaller number of large partners in key strategic markets and expects to see the benefits of these in 2022 and beyond”. What does that mean at the bottom-line?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Tuesday »


Synectics – a recovery Buy?



Malcolm Stacey is Moving House

Monday »


Wood Group - a Buy (again)?



Video: Bubbles always implode